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DOI 10.1016/j.ccr.2011.01.036SUMMARYThe Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal
Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, special-
ized membrane protrusions for extracellular matrix degradation. Twist1 induces PDGFRa expression, which
in turn activates Src, to promote invadopodia formation. We show that Twist1 and PDGFRa are central
mediators of invadopodia formation in response to various EMT-inducing signals. Induction of PDGFRa
and invadopodia is essential for Twist1 to promote tumormetastasis. Consistent with PDGFRa being a direct
transcriptional target of Twist1, coexpression of Twist1 and PDGFRa predicts poor survival in breast tumor
patients. Therefore, invadopodia-mediatedmatrix degradation is a key function of Twist1 in promoting tumor
metastasis.INTRODUCTION
During metastasis, carcinoma cells acquire the ability to invade
surrounding tissues and intravasate through the endothelium
to enter systemic circulation. Both the invasion and intravasation
processes require degradation of basement membrane and
extracellular matrix (ECM). Although proteolytic activity is asso-
ciated with increased metastasis and poor clinical outcome,
the molecular triggers for matrix degradation in tumor cells are
largely unknown.
Invadopodia are specialized actin-based membrane protru-
sions found in cancer cells that degrade ECM via localization
of proteases (Tarone et al., 1985, Chen, 1989). Their ability to
mediate focal ECM degradation suggests a critical role for inva-
dopodia in tumor invasion and metastasis. However, a definitive
role for invadopodia in local invasion and metastasis in vivo hasSignificance
Studies suggest that the EMT-inducing transcription factors pla
are the cellular functions and transcriptional targets of indivi
metastasis. Our study identifies a unique function of Twist1 in p
is essential for its ability to promote metastasis. Formation
different transcription factors. This explains why multiple facto
cells to undergo EMT and invade. We also identify PDGFRa as
podia formation and tumor metastasis, therefore suggesting
therapies.
372 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.not yet been clearly demonstrated. As actin-based structures,
invadopodia contain a primarily branched F-actin core and actin
regulatory proteins, such as cortactin, WASp, and the Arp2/3
complex (Linder, 2007). The SH3 domain-rich proteins Tks4
(Buschman et al., 2009) and Tks5 (Seals et al., 2005) function
as essential adaptor proteins in clustering structural and enzy-
matic components of invadopodia. The matrix degradation
activity of invadopodia has been associated with a large number
of proteases, including membrane type MMPs (MT1-MMP)
(Linder, 2007). Invadopodia formation requires tyrosine phos-
phorylation of several invadopodia components including
cortactin (Ayala et al., 2008), Tks4 (Buschman et al., 2009), and
Tks5 (Seals et al., 2005) by Src family kinases.
Our previous study found that the Twist1 transcription factor,
a key regulator of early embryonicmorphogenesis, was essential
for the ability of tumor cells to metastasize from the mammaryy critical roles in tumormetastasis. Amajor question is what
dual EMT-inducing transcription factors required for tumor
romoting invadopodia-mediated matrix degradation, which
of invadopodia and loss of cell adhesion are regulated by
rs need to be activated coordinately to promote carcinoma
a direct transcriptional target of Twist1 in promoting invado-
that PDGFRs might be potential targets for anti-metastasis
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Twist1-Induced Invadopodia Promote Metastasisgland to the lung in a mouse breast tumor model and was highly
expressed in invasive human lobular breast cancer (Yang et al.,
2004). Since then, studies have also associated Twist1 expres-
sion with many aggressive human cancers, such as melanomas,
neuroblastomas, prostate cancers, and gastric cancers (Pei-
nado et al., 2007). Twist1 can activate a latent developmental
program termed the epithelial-mesenchymal transition (EMT),
thus enabling carcinoma cells to dissociate from each other
and migrate.
The EMT program is a highly conserved developmental
program that promotes epithelial cell dissociation and migration
to different sites during embryogenesis. During EMT, cells lose
their epithelial characteristics, including cell adhesion and
polarity, and acquire a mesenchymal morphology and the ability
to migrate (Hay, 1995). Biochemically, cells downregulate
epithelial markers such as adherens junction proteins E-cadherin
and catenins and express mesenchymal markers including
vimentin and fibronectin (Boyer and Thiery, 1993). In addition
to Twist1, the zinc-finger transcription factors, including Snail,
Slug, ZEB1, and ZEB2 (Peinado et al., 2007), can also activate
the EMT program by directly binding the E-boxes of the E-cad-
herin promoter to suppress its transcription. However, it is
unclear how Twist1, as a bHLH transcription factor, controls
the EMT program. In this study, we test the hypothesis that
Twist1 plays a major role in regulating ECM degradation to
promote tumor metastasis.
RESULTS
Twist1 Is Necessary and Sufficient for Invadopodia
Formation and Function
Our previous studies found that Twist1 expression was associ-
ated with increased metastatic potentials in a series of mouse
mammary tumor cell lines, including 67NR, 168FARN, and 4T1
(Yang et al., 2004). Furthermore, Twist1 is required for the ability
of 4T1 cells to metastasize from the mammary gland to the lung.
To dissect the cellular functions of Twist1 in promoting tumor
metastasis, we first tested whether expression of Twist1 was
associated with increased ability to degrade ECM. 67NR,
168FARN, and 4T1 cells were plated onto FITC-conjugated
gelatin matrix to assess their abilities to degrade matrix. We
found that Twist1-expressing metastatic 168FARN and 4T1 cells
potently degraded ECM in 8 hr, while nonmetastatic 67NR cells
that do not express Twist1 failed to do so (Figures 1A–1C). To
test whether Twist1 is required for the ability of 168FARN and
4T1 cells to degrade ECM, 168FARN and 4T1 cells expressing
two independent shRNAs against Twist1 were processed for
the matrix degradation assay (Figure 1A). Indeed, we found
that suppressing Twist1 expression resulted in a potent reduc-
tion in matrix degradation in both cell types (Figures 1B and
1C). Together, these results demonstrate that Twist1 is required
for ECM degradation ability in tumor cells.
Localized matrix degradation can be mediated through actin-
based subcellular protrusions called invadopodia. Colocaliza-
tion of F-actin with the actin-bundling protein cortactin (Bowden
et al., 2006) or the unique adaptor protein Tks5 (Abram et al.,
2003) can be used to identify invadopodia. To determinewhether
invadopodia are present in 168FARN and 4T1 cells and whether
Twist1 is required for invadopodia formation, we examined thepresence of invadopodia in 168FARN and 4T1 cells by immuno-
fluorescence. Invadopodia are transient structures, so only
a fraction of cells possess invadopodia at any given time. Indeed,
over 50% 168FARN and 4T1 cells contain invadopodia, while
suppression of Twist1 expression reduced the occurrence of
invadopodia to 5%–20% in both cell lines (Figures 1D–1F; see
Figures S1A and S1B available online). These data indicate
that Twist1 is necessary for the formation of invadopodia for
ECM degradation.
Since 168FARN and 4T1 mouse tumor cells contain additional
genetic and epigenetic changes essential for their tumorigenic
and metastatic abilities (Mani et al., 2007), we next tested
whether Twist1 is sufficient to promote invadopodia formation
and matrix degradation in HMLE cells, immortalized normal
human mammary epithelial cells. As reported, expression of
Twist1 induced EMT in HMLE cells (Yang et al., 2004). We exam-
ined the presence of invadopodia and found that over 60% of
HMLE cells expressing Twist1 contained invadopodia,
compared with 10% of HMLE control cells with invadopodia
(Figures 2A and 2B; Figure S2A). Importantly, these invadopodia
were all localized to the basal surface of the cell directly adjacent
to the underlying matrix when examined with Z-sectioning
(Figure 2C). To determine whether these Twist1-induced invado-
podia are functional, we compared the ability of these two cell
lines to degrade matrix using the FITC-gelatin degradation
assay. Expression of Twist1 increased matrix degradation by
approximately 10-fold (Figures 2D and 2E). Strikingly, focal
matrix degradation precisely colocalized with F-actin positive
puncta (Figure 2D), indicating that Twist1 is sufficient to promote
the formation of functional invadopodia in HMLE cells. Further-
more, Twist1-induced matrix degradation is protease-driven
since suppression of metalloproteases by GM6001 inhibited
the ability of HMLE-Twist1 cells to degrade FITC-gelatin (Fig-
ure 2E). Together, these data demonstrate that Twist1 is both
necessary and sufficient to promote invadopodia formation
and focal matrix degradation.
Twist1-Mediated Matrix Degradation Is Invadopodia-
Driven and Src Dependent
Since both invadopodia-associated proteases and secreted
proteases can mediate matrix degradation, we next set out to
determine whether invadopodia, not secreted proteases, are
solely responsible for Twist1-induced matrix degradation. In
HMLE-Twist1 cells, we expressed shRNAs against Tks5, an
adaptor protein that is required for invadopodia formation,
but not MMP secretion (Seals et al., 2005). Both shRNAs effec-
tively suppressed Tks5 expression (Figure S3A), and gelatin
zymography showed that knockdown of Tks5 did not affect
the secretion of proteases, mainly MMP2, into conditioned
media (Figure S3B). In contrast, suppression of Tks5 signifi-
cantly reduced their abilities to form invadopodia (Figures 3A
and 3B) and degrade FITC-gelatin matrix (Figure 3C). Comple-
mentary to these data, Boyden chamber migration and invasion
assays showed that suppression of Tks5 inhibited the ability of
HMLE-Twist1 cells to invade through Matrigel, but did not
affect cell migration (Figures S3C and S3D). Together, these
results demonstrate that the protease activity associated with
invadopodia is the sole mediator of Twist1-induced matrix
degradation.Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 373
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Figure 1. Twist1 Is Necessary for Invadopodia Formation
(A) Indicated cell lysates were analyzed by SDS-PAGE and probed for Twist1 and b-actin.
(B) 67NR, 168FARN (expressing control or Twist1 knockdown shRNA), and 4T1 (expressing control or Twist1 knockdown shRNA) cells were plated on FITC-
conjugated gelatin (green) for 8 hr. F-actin was stained with phalloidin (red) and nuclei with DAPI (blue). Areas of gelatin degradation appear as punctuate black
areas beneath the cells.
(C) Quantification of FITC-gelatin degradation. N = 150 cells/sample. *p < 0.02.
(D and E) 168FARN and 4T1 cells expressing control or Twist1 shRNAs were stained with phalloidin (red), DAPI (blue), and cortactin (green).
(F) Quantification of percentage of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
Error bars are standard error of mean (SEM). Scale bars are 1 mm for insets, 5 mm for full images.
See also Figure S1.
Cancer Cell
Twist1-Induced Invadopodia Promote MetastasisWe next set out to understand how Twist1 promotes invado-
podia formation. While no transcription factor has been impli-
cated in invadopodia regulation, tyrosine phosphorylation of
invadopodia components, including cortactin and Tks5, is
necessary for invadopodia formation (Ayala et al., 2008). We
therefore assessed whether tyrosine phosphorylation at invado-374 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.podia was increased in HMLE-Twist1 cells. Immunofluores-
cence staining with a phosphotyrosine antibody revealed enrich-
ment of phosphotyrosine at invadopodia (Figure 3D). Cortactin
immunoprecipitated from HMLE-Twist1 cells also showed
increased tyrosine phosphorylation compared to HMLE control
cells (Figure 3E).
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Figure 2. Twist1 Is Sufficient to Promote Invadopodia Formation
(A) HMLE cells expressing a control vector or Twist1 were plated on 0.2% gelatin matrix for 72 hr and invadopodia were visualized by colocalization of cortactin
(green) and F-actin (red).
(B) Quantification of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
(C) Colocalization of F-actin (red) and cortactin (green) is restricted to the basal side of cells in direct contact with the underlying matrix.
(D) HMLE control or HMLE-Twist1 cells were plated on FITC-gelatin for 8 hr and stained for F-actin (red) and nuclei (blue).
(E) Quantification of degradation by HMLE-ctrl and HMLE-Twist1 cells and HMLE-Twist1 cells treated with 25 mM GM6001 Negative Control (GMNC) or 25 mM
GM6001 for 8 hr. N = 150 cells/sample. *p < 0.02.
Error bars are SEM. Scale bars are 1 mm for insets, 5 mm for full images.
See also Figure S2.
Cancer Cell
Twist1-Induced Invadopodia Promote MetastasisSrc family kinases are the major kinases that promote tyrosine
phosphorylation and formation of invadopodia. We therefore
examined whether Twist1 induced expression of any of the three
major Src family kinases, Src, Yes, and Fyn. Both real-time RT-
PCRand immunoblotting analyses showed that none of the three
Src kinases were greatly induced by Twist1 (Figures S3E and
S3F; Figure 3E). Interestingly, when we probed for the activation
status of Src, Yes, and Fyn in HMLE-Twist1 cells using an anti-
body recognizing the active form of Src family kinases (phospho-
tyrosine 416), Src was significantly activated upon Twist1
expression (Figure 3E), while Yes and Fyn phosphorylation
remained constant (Figure S3F). These data suggest that activa-
tion of Src kinase activity, but not transcriptional induction of Src
kinase expression, might be responsible for tyrosine phosphor-
ylation at invadopodia in HMLE-Twist1 cells. To determine
whether Src kinase activity is required for Twist1-induced inva-
dopodia function, we treated HMLE-Twist1 cells with SU6656,
a selective inhibitor of Src family kinases (Blake et al., 2000) (Fig-
ure S3G) or expressed a dominant-negative Src (SrcK295M/Y527F)
(Figure S3H). Both treatments reduced the ability of HMLE-
Twist1 cells to degrade matrix by 5-fold (Figure 3F), indicating
that Src kinase activity is essential for Twist1-mediated invado-
podia function. Treatment with SU6656 also inhibited colocaliza-
tion of the phosphotyrosine signal with F-actin (Figure 3D) and
caused a significant reduction in the number of cells that formedinvadopodia (Figure 3G). Together, these results indicate that
Twist1-induced invadopodia formation and function is depen-
dent on activation of the Src kinase.
Twist1-Induced PDGFR Expression and Activation
Is Required for Invadopodia Formation
As a transcription factor, Twist1 cannot directly activate Src
kinase, so we probed how Twist1 promotes activation of Src in
HMLE-Twist1 cells. Since activation of Src kinase is downstream
of growth factor receptor (GFR) activation, we examined induc-
tion of known GFRs upstream of Src by Twist1. Using an induc-
ible Twist1 (Twist1-ER) construct (Mani et al., 2008), we found
that expression of PDGFRa mRNAs increased 3-fold within
3 hr of Twist1 activation and reached over 6000-fold induction
at Day 15, while induction of PDGFRb mRNAs occurred signifi-
cantly later (Figure 4A). PDGFRs can directly activate Src family
kinases by tyrosine phosphorylation (Kypta et al., 1990), and
activation of a PDGF autocrine loop is associated with the EMT
program (Jechlinger et al., 2003). We found that PDGFRa and
b proteins were also induced in HMLE-Twist1 cells and both
PDGFR a and bwere phosphorylated at tyrosine residues corre-
sponding to their active states (Figure 4B). This activation of
PDGFR without exogenous PDGF ligands implies the existence
of an autocrine activation loop in vitro most likely mediated by
PDGF-C, the only PDGF ligand significantly expressed andCancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 375
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Figure 3. Twist1-Mediated Matrix Degradation Is Invadopodia Driven and Src Dependent
(A) HMLE-Twist1 cells expressing a control or Tks5 shRNA were plated on 0.2% gelatin and stained for Tks5 (green) or phosphotyrosine (green) and F-actin (red).
(B) Quantification of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
(C) Quantification of FITC-gelatin degradation. N = 150 cells/sample. *p < 0.02.
(D) HMLE-Twist1 cells were plated on 0.2% gelatin and treated with treated with DMSO or 5 mM SU6656 for 12 hr and stained for phosphotyrosine (green) and
F-actin (red).
(E) Cortactin and Src were immunoprecipitated from HMLE control and HMLE-Twist1 cell lysates, analyzed by SDS-PAGE, and probed for cortactin and phos-
photyrosine and Src and pTyr416Src, respectively. Input lysates were probed for b-actin, Src, and cortactin.
(F) Quantification of FITC-gelatin degradation. Indicated cells were treated with 5 mMSU6656 or DMSO for 12 hr or transfected with control or SrcK295M/Y527F
vectors. N = 150 cells/sample. *p < 0.02.
(G) Quantification of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
Error bars are SEM. Scale bars are 1 mm for insets, 5 mm for full images.
See also Figure S3.
Cancer Cell
Twist1-Induced Invadopodia Promote Metastasisupregulated upon activation of Twist1 inHMLEcells (Figure S4A).
Upregulation of PDGFRs by Twist1 therefore presented a poten-
tial mechanism for activation of Src by Twist1.
We next set out to determine whether activation of PDGFRs
is required for Twist1-induced invadopodia formation and376 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.matrix degradation. Given the immediate and robust induction
of PDGFRa upon Twist1 activation, we focused on inhibiting
PDGFRa to examine its role in mediating Twist1-induced Src
activation and invadopodia formation. We first treated the
HMLE-Twist1 cells with a monoclonal blocking antibody
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Figure 4. Twist1-Induced PDGFR Expression and Activation Is Required for Invadopodia Formation
(A) Real-time PCR analysis of PDGFRa and PDGFRb expression in HMLE-Twist1-ER cells treated with 20 nM 4-hydroxy-tamoxifen.
(B) Cell lysates from HMLE control, HMLE-Twist1 cells, HMLE-Twist1 cells treated with vehicle or 8 mg/ml PDGFRa blocking antibody (ctrl and mAb), and HMLE-
Twist1 cells expressing control (shC) or PDGFR (sha1 and 3) shRNA were analyzed by SDS-PAGE and probed for b-actin, PDGFRa, PDGFRb, pTyr754PDGFRa,
and pTyr1009PDGFRb.
(C) Cortactin and Src were immunoprecipitated from cell lysates of HMLE-Twist1 cells treated with 8 mg/ml PDGFRa blocking antibody (mAb) or vehicle control
(ctrl) or HMLE-Twist1 cells expressing indicated shRNAs (control, shC; shPDGFRa, sha1 and sha3) and probed for total cortactin and phosphotyrosine or total
Src and pTyr419Src, respectively. Input lysates were probed for b-actin, cortactin, and total Src.
(D) HMLE-Twist1 cells were seeded on 0.2% gelatin and treated for 24 hr with 8 mg/ml PDGFRa blocking antibody (aPDGFRa) or vehicle control and stained for
phosphotyrosine (green), F-actin (red), and nuclei (blue). Scale bars are 1 mm for insets, 5 mm for full images.
(E) Quantification of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
(F) Quantification of FITC-gelatin degradation. N = 150 cells/sample. *p < 0.02.
Error bars are SEM.
See also Figure S4.
Cancer Cell
Twist1-Induced Invadopodia Promote Metastasisagainst PDGFRa and examined invadopodia formation and
matrix degradation. This antibody effectively inhibited PDGFRa
activation (Figure 4B), Src activation, and tyrosine phosphoryla-
tion of cortactin in HMLE-Twist1 cells (Figure 4C). This PDGFRa
blocking antibody significantly inhibited invadopodia formation
and tyrosine phosphorylation at invadopodia and suppressed
the ability of HMLE-Twist1 cells to degrade FITC-gelatin by
over 5-fold (Figures 4D–4F). To verify the results observed
with the PDGFRa blocking antibody, we also expressed two
independent shRNAs against PDGFRa in HMLE-Twist1 cellsto stably suppress and inhibit PDGFRa signaling. Both shRNAs
potently suppressed PDGFRa expression (Figure 4B), Src acti-
vation, and cortactin phosphorylation (Figure 4C), and effec-
tively suppressed the ability of HMLE-Twist1 cells to degrade
matrix (Figure 4F). Importantly, expression or secretion of
proteases was not affected by PDGFRa knockdown as
measured with gelatin zymography (Figure S4B). Together,
these data indicate that PDGFRa expression and activation is
required for Twist1-induced invadopodia formation and
invasion.Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 377
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Figure 5. Twist1 Is Required for Snail-Induced Invadopodia Formation
(A) HMLE-Snail cells expressing indicated shRNA were seeded on 0.2% gelatin for 72 hr, and stained for cortactin (green), F-actin (red), and nuclei (blue).
(B) Quantification of cells with invadopodia. N = 150 cells/sample. *p < 0.02.
(C) HMLE-Snail cells expressing control or Twist1 shRNA were seeded on FITC-gelatin (green) for 8 hr and stained for F-actin (red) and nuclei (blue).
(D) Quantification of FITC-gelatin degradation. N = 150 cells/sample. *p < 0.02.
(E) Real-time PCR analysis of PDGFRa and Twist1 mRNA expression in HMLE-Snail-ER cells treated with 20 nM 4-hydroxy-tamoxifen.
(F) Cell lysates from indicated cells were analyzed by SDS-PAGE and probed for PDGFRa, Twist1, and b-actin.
Error bars are SEM. Scale bars are 1 mm for insets, 5 mm for full images.
See also Figure S5.
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Twist1-Induced Invadopodia Promote MetastasisWe also examined expression of PDGFRa in 168FARN cells
expressing control and Twist1 knockdown constructs. PDGFRa
was highly expressed in control cells and significantly reduced
upon knockdown of Twist1 (Figure S4C). These results provide
further evidence that expression of PDGFRa depends on the
presence of Twist1 in breast tumor cells.
Twist1 Is a Central Mediator of Invadopodia Formation
in Response to EMT-Inducing Signals
Since other inducers of EMT, such as TGFb and Snail, have also
been associated with tumor invasion and metastasis, we sought
to understand whether invadopodia formation also occurs in
response to other EMT-inducing signals and whether Twist1
mediates invadopodia formation in response to these signals.
To do so, we first tested the ability of Snail, another EMT-
inducing transcription factor, to promote invadopodia formation
and matrix degradation. As previously reported, Snail overex-
pression induces EMT similarly to Twist1 in HMLE cells (Mani
et al., 2008). HMLE-Snail cells have similar numbers of invado-378 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.podia and ECM-degradation activities as HMLE-Twist1 cells
(Figures 5A–5D). To determine whether Snail, like Twist1, could
induce the expression of PDGFRa to promote invadopodia
formation, we examined the expression of PDGFRa mRNA in
HMLE cells that express an inducible Snail (Snail-ER) construct.
In contrast to the immediate induction of PDGFRa upon Twist1
activation, PDGFRa mRNA only began to increase 6 days after
Snail activation, indicating that induction of PDGFRa by Snail
is indirect (Figure 5E). Interestingly, endogenous Twist1 mRNA
levels increased significantly after 4 days of Snail activation,
before PDGFRa mRNA began to increase (Figure 5E). These
data suggest that induction of endogenous Twist1 could be
responsible for PDGFRa expression and invadopodia formation
upon Snail activation.
To assesswhether Twist1mediates the induction of invadopo-
dia and PDGFRa in HMLE-Snail cells, we expressed shRNAs
against endogenous Twist1 in HMLE-Snail cells. Indeed,
suppression of endogenous Twist1 significantly inhibited
expression of PDGFRa in HMLE-Snail cells (Figure 5F).
Cancer Cell
Twist1-Induced Invadopodia Promote MetastasisSignificantly, suppression of Twist1 expression inhibited invado-
podia formation in HMLE-Snail cells and reduced their ability to
degrade matrix (Figures 5A–5D). Importantly, HMLE-Snail cells
that express shRNAs against Twist1 presented an EMT pheno-
type with loss of E-cadherin expression and a mesenchymal
morphology (Figures S5A and S5B), indicating that suppression
of E-cadherin by Snail and induction of invadopodia by Twist1
are regulated independently. Treating HMLE-Snail cells with
the PDGFRa blocking antibody also significantly suppressed
the ability of HMLE-Snail cells to degrade FITC-gelatin (Figures
S5C and S5D). Together, these results indicate that Twist1 and
PDGFRa are responsible for invadopodia formation in response
to Snail activation.
To further generalize our finding, we also investigated the role
of Twist1 and PDGFRa in regulating invadopodia formation in
response to TGFb. In EpH4 mouse mammary epithelial cells,
TGFb has been shown to collaborate with Ras to promote EMT
and activates an autocrine PDGF loop (Jechlinger et al., 2003).
When we examined the invadopodia formation and matrix
degradation in EpH4-Ras cells treated with TGFb, we found
that TGFb treatment induced over 5-fold increase of invadopodia
formation and matrix degradation in 2D culture (Figures 6A–6C).
When these cells grew in 3D culture with TGFb, invadopodia
were visible at the leading edge of cells invading out of the orga-
noids (Figure 6E). Interestingly, both Twist1 and PDGFRa were
induced in response to TGFb treatment (Figure 6D). When
endogenous Twist1 induction was inhibited by shRNAs, invado-
podia formation and matrix degradation were significantly
reduced in 2D and 3D cultures (Figures 6A–6C and 6E). Impor-
tantly, knocking down Twist1 abolished induction of PDGFRa
in EpH4-Ras cells treated with TGFb (Figure 6D), but did not
prevent induction of EMTmorphogenesis and loss of E-cadherin
(Figures S6A and S6B), similar to knockdown of Twist1 in HMLE-
Snail cells. Furthermore, treating EpH4-Ras cells with the
PDGFRa inhibitor ST1571 significantly suppressed their ability
to degrade FITC-gelatin in response to TGFb treatment (Figures
S6C and S6D). Importantly, treatment with STI571 did not revert
the EMTphenotype (Figure S6E). Together, these results support
our conclusion that Twist1 is a central mediator of invadopodia
formation and matrix degradation via induction of PDGFRa in
response to EMT-inducing signals.
Twist1-Induced Metastasis Is Mediated by Invadopodia
In Vivo and Requires PDGFRa
Twist1 is required for mammary tumor cells to metastasize from
the mammary gland to the lung. We then tested whether
PDGFRa and invadopodia are required for the ability of Twist1
to promote tumor metastasis in vivo. To do so, we generated
HMLE-Twist1 cells that were transformed with oncogenic Ras
(HMLER-Twist1) and expressed shRNAs against either PDGFRa
or a control shRNA. These cells also expressed GFP to allow
identification of tumor cells in mice. Individual cell lines were in-
jected subcutaneously into nude mice. Suppression of PDGFRa
did not affect cell proliferation in culture or tumor growth rate
in vivo (Figures S7A and S7B). Six weeks after tumor implanta-
tion, we sacrificed the mice and examined primary tumors for
histology and invadopodia. Since HMLER-Twist1 tumors ex-
pressing large T antigen, we used an antibody against large
T antigen to stain implanted tumor cells. Interestingly, HMLER-Twist1 tumor cells invaded into surrounding stroma and adjacent
adipose tissue, while PDGFRa knockdown inhibited local inva-
sion and tumor cells remained encapsulated (Figure 7A). Stain-
ing for invadopodia using cortactin and Tks5 in sections of
primary tumor tissue revealed that HMLER-Twist1 tumor cells
contained abundant invadopodia, while knocking down
PDGFRa significantly reduced their occurrence (Figures 7B
and 7C). To test whether PDGFRa is required for distant metas-
tasis, examination of lung lobes and sections revealed clusters of
HMLER-Twist1 shControl cells throughout the lungs (Figure 7E;
Figure S7E). Significantly, suppression of PDGFRa expression
significantly reduced the number of disseminated tumor cells
in the lung (Figure 7D). These results strongly indicate that induc-
tion of PDGFRa is required for the ability of Twist1 to form inva-
dopodia and promote tumor metastasis without affecting
primary tumor growth in vivo.
To demonstrate that invadopodia are required for the ability of
Twist1 to metastasize in vivo, we expressed shRNAs against
Tks5 to inhibit invadopodia formation in HMLER-Twist1 cells.
Knockdown of Tks5 did not affect cell growth rate in vitro (Fig-
ure S7C), which is consistent with a previous study (Blouw
et al., 2008).’’. These cells were implanted subcutaneously into
nude mice to follow primary tumor growth and lung metastasis.
Consistent with the results from the PDGFRa knockdown exper-
iments, Tks5 knockdown inhibited local tumor invasion and
significantly reduced the numbers of tumor cells that dissemi-
nated into the lung, while primary tumor growth was not affected
(Figures 7A, 7D, and 7E; Figure S7D). Together, these data
demonstrate that induction of invadopodia formation via
PDGFRa activation is essential for the ability of Twist1 to
promote tumor metastasis in vivo.
PDGFRa Is a Direct Transcription Target of Twist1
and Expression of Twist1 and PDGFRa Are Tightly
Linked in Human Breast Tumors
Given the immediate induction of PDGFRa by Twist1 and their
tight association in various tumor cells, we set out to determine
whether PDGFRa is a direct transcriptional target of Twist1.
We examined the human PDGFRa promoter for potential
Twist1-binding E-box sequences (CANNTG). We designed three
sets of primers on the putative promoter: primer sets 1 and 2
target the identified E-box, and primer set 3 targets an adjacent
region lacking the putative E-box (Figure 8A). By chromatin
immunoprecipitation, we found that Twist1 directly bound to
the E-box on the putative PDGFRa promoter (Figure 8B). Twist1
was able to activate the isolated human PDGFRa promoter in an
E-box-dependent fashion in a luciferase reporter assay (Figures
S8A and S8B). Furthermore, this consensus E-box sequence is
highly conserved between all mammalian species examined
and chickens (Figure 8C), indicating that induction of PDGFRa
by Twist1 is direct and evolutionally conserved.
To more directly probe the in vivo association between Twist1
and PDGFRa in human breast tumor samples, we analyzed four
published large human breast tumor gene expression data sets
summarizing 860 primary breast cancers (Pawitan et al., 2005;
Sotiriou et al., 2006; Wang et al., 2005; Miller et al., 2005). In
each data set, we calculated the rank-based Spearman correla-
tion coefficient between Twist1 and all 22282 genes on the array,
including PDGFRa. PDGFRa was consistently among the topCancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 379
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Figure 6. Twist1 Is Required for TGFb-Induced Invadopodia Formation in Eph4Ras Cells
(A) Eph4Ras cells expressing control or Twist1 shRNAs were seeded on 0.2% gelatin for 72 hr before and after treatment with 5 ng/ml TGFb1 for 7 days and
stained for cortactin (green), F-actin (red), and nuclei (blue).
(B) Quantification of cells with invadopodia before and after 7 days of 5 ng/ml TGFb1 treatment for EpH4Ras cells expressing indicated shRNAs. N = 150 cells/
sample. *p < 0.02.
(C) Quantification of FITC-gelatin degradation for cells expressing indicated shRNA before and after 7 days of 5 ng/ml TGFb1 treatment. N = 150 cells/sample.
*p < 0.02.
(D) Cell lysates from indicated cells before and after treatment with 5 ng/ml TGFb1 for 7 days were analyzed by SDS-PAGE and probed for PDGFRa, Twist1, and
b-actin.
(E) Indicated cells were embedded in 1:1mixture ofMatrigel and collagen, allowed to form 3D structures, and processed for IF before and after 7 days of induction
with 7 ng/ml TGFb1. Cells were stained for Tks5 (green) and F-actin (red).
Error bars are SEM. Scale bars are 1 mm for insets, 5 mm for full images.
See also Figure S6.
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Twist1-Induced Invadopodia Promote Metastasisranked genes associated with Twist1 (4th, 17th, 47th, and 54th
out of 22,282 genes) in all four breast cancer data sets (Figure 8D;
Figure S8D). Expression of Twist1 and PDGFRa were positively
correlated with correlation coefficients ranging from 0.56 to380 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.0.70 (Figure 8D; Figure S8C). Furthermore, in all four data sets,
PDGF ligand expression correlated with PDGFRa and Twist1
expression in over 95% of tumor samples (Table S1), indicating
that PDGFRa could be active in these samples. To further access
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Figure 7. Twist1-Induced Metastasis Is Mediated by Invadopodia In Vivo and Requires PDGFRa
(A) Representative images of primary tumor paraffin tissue sections stained with SV40 Large-T antigen IHC and counterstained with hematoxylin. Tumormargin is
indicated with dashed line when apparent. Closed triangles indicate invasive, Large-T positive tumor cells. Asterisks indicate adjacent adipose tissue. Scale bars
are 100 mm.
(B) Images of sections of primary tumors stained with cortactin (green), Tks5 (red), and DAPI (blue). Scale bars are 1 mm for insets, 5 mm for full images.
(C) Quantification of number of invadopodia (cortactin/Tks5 colocalization) per cell. N = 150 cells/sample. *p < 0.02.
(D) Quantification of total number of GFP positive tumor cells (HMLER-Twist1 cells expressing indicated shRNAs) in individual lungs. N = 5 mice per group.
(E) Representative images of lungs frommice injected with HMLER-Twist1 cells expressing indicated shRNAs show a decrease in dissemination of GFP positive
tumor cells (green) to the lungs upon knockdown of PDGFRa or Tks5.
Error bars are SEM.
See also Figure S7.
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Twist1-Induced Invadopodia Promote Metastasiswhether coexpression of Twist1 and PDGFRa could affect
survival in breast tumor patients, we stained Twist1 and PDGFRa
in a set of human invasive breast tumor tissue array samples and
found that coexpression of Twist1 and PDGFRa was negatively
associatedwith long-term survival (Figures 8E and 8F). Together,
these data provide further support for a direct and functional
association between Twist1 and PDGFRa in human breast
cancers and suggest that regulation of invadopodia by Twist1
and PDGFRa contributes to human breast cancer progression.DISCUSSION
Our study has identified a unique function of the Twist1 tran-
scription factor in promoting invadopodia formation and matrix
degradation during tumormetastasis. We demonstrate that tran-
scriptional induction of PDGFRa and activation of Src by Twist1
are essential for invadopodia formation and matrix degradation.
Induction of PDGFRa and invadopodia formation is also essen-
tial for the ability of Twist1 to promote metastasis in vivo. Twist1Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 381
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Cancer Cell
Twist1-Induced Invadopodia Promote Metastasisand PDGFRa are central mediators of invadopodia in response
to several EMT-inducing signals. Finally, we provide evidence
for a tight association between Twist1 and PDGFRa in human
breast tumor samples.
Induction of Invadopodia by Twist1 Plays a Key Role
in Extracellular Matrix Degradation and Metastasis
ECM degradation is considered a key step promoting tumor
invasion and metastasis. Extensive studies have largely focused
on secreted MMPs as key proteases in tumor invasion. More
recent studies suggest a role for invadopodia and their associ-
ated proteases in localized matrix degradation during cell inva-
sion. Conceptually, invadopodia provide an elegant solution to
restrict protease activity to areas of the cell in direct contact
with ECM, thus precisely controlling cell invasion in vivo. In this
study, we show that Twist1, a key transcription factor in tumor
metastasis, is both necessary and sufficient to promote invado-
podia formation. Importantly, invadopodia formation is required
for the ability of Twist1 to promote tumor metastasis in vivo.
Together, these results demonstrate an essential role for invado-
podia in tumor invasion and metastasis in vivo.
How invadopodia formation is regulated at the molecular level
is still not well understood. Our current study indicates that
Twist1 directly induces the expression and activation of
PDGFRa, thus promoting Src kinase activation and invadopodia
formation. Although we did not detect induction of several
important invadopodia proteins, including cortactin, Tks4,
Tks5, and MT1-MMP, by Twist1 (data not shown), we are
actively exploring additional mechanisms by which Twist1 regu-
lates invadopodia.
Another question arising from our study is whether invadopo-
dia function is required for the EMT process. Epithelial cells sit on
top of a layer of basement membrane. For the EMT program to
occur in vivo, these cells must breach the underlying basement
membrane to dissociate (Nakaya et al., 2008). Little is known
about the functional relationship between basement membrane
integrity and the EMT program. In HMLE-Snail cells and EpH4-
Ras cells treated with TGFb, knockdown of Twist1 inhibited
invadopodia formation, while these cells underwent the morpho-
logical changes associated with EMT and lost E-cadherin
expression. Additionally, knockdown of Tks5, a required compo-
nent of invadopodia, did not revert the EMT phenotype in HMLE-
Twist1 cells. These results indicate that invadopodia function is
not essential for EMT to occur in 2D cultures. However, it is plau-
sible that the EMT program requires activation of Twist1 and in-
vadopodia formation to allow degradation of the basement
membrane in vivo. Studies in vivo or in 3D cultures with intact
basement membrane are required to fully answer this question.
Twist1 and Snail Have Distinct Cellular Functions
and Transcriptional Targets
The EMT program is considered a key event promoting carci-
noma cell dissociation, invasion, and metastasis. Several tran-
scription factors, including Snail, Slug, ZEB1, ZEB2, and Twist1,
promote EMT in epithelial cells (Peinado et al., 2007). During
mesoderm formation and neural crest development, these tran-
scription factors are activated to allow the dissociation and
migration of epithelial cells. A major unsolved question is to
determine the distinct cellular functions and molecular targetsof individual EMT-inducing transcription factors. Extensive
studies in recent years have demonstrated that Snail (Batlle
et al., 2000; Cano et al., 2000), Slug (Hajra et al., 2002), and
ZEB2 (Comijn et al., 2001), all zinc-finger-containing transcrip-
tional repressors, directly bind to the E-boxes on the E-cadherin
promoter and suppress its transcription. In this study, we identi-
fied a unique function of Twist1 in promoting matrix degradation
via invadopodia. We show that Twist1 functions as a transcrip-
tional activator to directly induce the expression of PDGFRa, in
contrast to the EMT-inducing Zn-finger transcription factors.
Vertebrate Twist1 lacks a transcription activation domain and
requires dimerization with other bHLH transcription factors to
activate transcription. Previous studies have shown Twist1 het-
erodimers with MyoD function as transcriptional repressors
(Hamamori et al., 1997). In contrast, heterodimerization with
E12 enables Twist1 to activate FGF2 transcription (Laursen
et al., 2007). Here, we demonstrate that Twist1 functions as
a transcriptional activator to directly induce the transcription of
PDGFRa. Twist1 might function as an activator or repressor of
transcription based on dimerization partners under different
physiological and cellular environments. The factors that hetero-
dimerize with Twist1 to activate PDGFRa transcription remain
unknown, although the E12/E47 proteins could perform this
function.
The Pathway Linking Twist1, PDGFR, and Invadopodia
Is Likely to Play a Conserved Role in Matrix Degradation
during Both Tumor Metastasis and Embryonic
Morphogenesis
Twist1 has been associated with increased metastasis in both
experimental tumor metastasis models and in many types of
human cancers. Interestingly, PDGFRa overexpression and acti-
vation have also been observed in aggressive human breast
tumors (Seymour and Bezwoda, 1994; Jechlinger et al., 2006).
Activation of PDGFRs was first observed in TGFb-induced
EMT and shown to be involved in cell survival during EMT and
experimental metastasis in mice (Jechlinger et al., 2006). Here,
we demonstrated a role of PDGFRa in invadopodia formation
and matrix degradation during tumor metastasis. Interestingly,
suppression of PDGFRa had no significant effects on cell prolif-
eration or survival in vitro and in vivo. These results could be due
to the greater specificity of shRNAs compared with chemical
inhibition as well as differences in cellular and signaling contexts.
Indeed, we found that STI571 (Gleevec), a c-ABL and c-Kit inhib-
itor that also inhibits PDGFR at a higher concentration, sup-
pressed Twist1-induced invadopodia formation and matrix
degradation. However, long-term (4 days) treatment with
STI571 resulted in cell toxicity in HMLE-Twist1 cells (data not
shown).
Our analyses identified Twist1 as a transcription inducer of
PDGFRa and demonstrate a tight correlation between the
expression level of Twist1 and PDGFRa in four large human
breast tumor gene expression studies. Interestingly, PDGF
ligand was also present in over 95% of tumor samples that
expressed Twist1 and PDGFRa, indicating PDGFRa is activated
in these tumors. Although these two genes alone are not suffi-
cient to predict survival with statistical significance in these
studies, these data, together with our metastasis data in mice
and human breast cancer tissue array data, strongly suggestCancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc. 383
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scription factor, is difficult to target therapeutically. As a down-
stream target of Twist1 with roles in tumor invasion, PDGFRa
might be a potentially valuable target for future therapeutics
against metastasis.
Although our study focuses on the role of Twist1-induced inva-
dopodia in metastasis, it also has important implications in
development. Twist1 null mice and PDGFRa null mice both
show defects in cranial neural crest development (Chen and
Behringer, 1995, Sun et al., 2000). In addition, the expression
pattern of Twist1 and PDGFRa are similar along the developing
neural crest and craniofacial region in developing mouse
embryos (Gitelman, 1997, Takakura et al., 1997). Our identifica-
tion of PDGFRa as a highly conserved transcriptional target of
Twist1 suggests that the pathway linking Twist1, PDGFRa, and
invadopodia might play a key role in regulating neural crest
development. Reactivation of this developmental machinery in
tumor metastasis is another example of an important develop-
mental pathway regulating tumor progression.
EXPERIMENTAL PROCEDURES
Cell Lines
67NR, 168FARN, 4T1 cells and the humanmammary epithelial cell lines HMLE
and HMLER were cultured as described (Yang et al., 2004). EpH4Ras cells
were passaged in mammary epithelial growth media (MEGM) mixed 1:1 with
DMEM/F12 supplemented with human EGF, insulin, and hydrocortisone.
Viral Production and Infection
Stable cell lines were created via infection of target cells using either lentivi-
ruses or Moloney viruses. 293T cells were seeded at 1 3 106 cells per 6 cm
dish in DMEM/10%FBS. After 18 hr, cells were transfected as follows: 6 ml
TransIT-LT1 (Mirus Bio) was added to 150 ml DMEM and incubated 20 min.
One microgram of viral vector along with 0.9 mg of the appropriate gag/pol
expression vector (pUMCV3 for pBabe or pWZL or pCMVD8.2R for lentiviral
vectors) and 0.1 mg VSVG expression vector were then added to the DMEM/
LT-1 mixture. The mixture was incubated 30 min and then added to 293T cells
overnight. Next day freshmedia were added to the transfected 293T cells. Viral
supernatant was harvested at 48 and 72 hr posttransfection, filtered, and
added to the recipient cell lines with 6 mg/ml protamine sulfate for 4 hr infection.
HMLE and EpH4Ras cells were then selected with 2 mg/ml puromycin, or
10 mg/ml blasticidin.
Plasmids
The Twist1 and Snail cDNAs and the Twist1-ER and Snail-ER in the pWZL-
Blast vector were described in Mani et al., 2009. The three shRNA lentiviral
constructs against Twist1 in the pSP108 vector were described in Yang
et al. (2004). The shRNA lentiviral constructs against Tks5 in the pLKO vector
were provided by Dr. Sara Courtneidge. The shRNAmir lentiviral constructs
against PDGFRa in the pGIPZ vector were purchased from Open Biosystems.
The oncogenic Ras (V12) was cloned into the pRRL lentiviral vector.
Real-Time PCR
Total RNAs were extracted from cells at 80%–90% confluency using RNeasy
Mini Kit coupled with DNase treatment (QIAGEN) and reverse transcribed with
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Result-
ing cDNAs were analyzed in triplicates using SYBR-Green Master PCR mix
(Applied Biosystems). Relative mRNA concentrations were determined by
2-(Ct-Cc) where Ct and Cc are the mean threshold cycle differences after
normalizing to GAPDH values. Primers used for PCR are listed in Supplemental
Experimental Procedures.
Immunoprecipitation
Cells at 80%–90% confluence were washed with PBS containing 100 mM
Na3VO4 and lysed in lysis buffer (50 mM Tris-HCL [pH 7.5], 150 mM NaCl,384 Cancer Cell 19, 372–386, March 15, 2011 ª2011 Elsevier Inc.1% Triton X-100, 10 mM NaF, 100 mM Na3VO4, 2 mM DTT) containing 1:50
dilution Protease Inhibitor Cocktail Set III (Calbiochem). For immunoprecipita-
tions, lysates were incubated with antibodies overnight at 4C. Fifty microliters
Protein G-Sepharose 4B conjugated beads (Invitrogen) was added for 12 hr at
4C. Beads were washed in lysis buffer and in PBS containing 100 mMNa3VO4.
Proteins were eluted from beads using SDS sample buffer and analyzed on
4%–12% precast SDS gels (PAGEgel).In Situ Zymography
This protocol is adapted from Artym et al. (2009). In brief, 12 mm coverslips
were incubated in 20% nitric acid for 2 hr and washed in H2O for 4 hr. Cover-
slips were incubated with 50 mg/ml poly-L-lysine/PBS for 15 min followed by
PBS washes before 0.15% gluteraldehyde/PBS was added for 10 min, fol-
lowed by PBS washes. Coverslips were inverted onto 20 ml droplets of 1:9
0.1% fluorescein isothiocyante (FITC)-gelatin (Invitrogen): 0.2% porcine
gelatin for 10 min. Coverslips were washed in PBS and then incubated
15 min in 5 mg/ml NaBH4. Coverslips were rinsed in PBS and incubated at
37 in 10% calf serum/DMEM for 2 hr. Twenty thousand cells were seeded
on each coverslip, incubated for 8 hr, and processed for immunofluorescence.
Each experiment was performed in triplicate. Images were taken at ten fields
per sample for a total of approximately 150 cells per sample. Gelatin degrada-
tion was quantified using ImageJ software. To measure the percentage of
degraded area in each field, identical signal threshold for the FITC-gelatin fluo-
rescence are set for all images in an experiment and the degraded area with
FITC signal below the set threshold was measured by ImageJ. The resulting
percentage of degradation area was further normalized to total cell number
(counted by DAPI staining for nuclei) in each field. The final gel degradation
index is the average percentage degradation per cell obtained from all ten
fields. Each experiment was repeated at least three times.Immunofluorescence
Matrix substrates were prepared using 0.2% porcine gelatin as for in situ
zymography. Cells were fixed at 37C in 4% paraformaldehyde (PFA)/PBS
with 50 mM CaCl2 for 15 min, permeabilized with 0.1% Triton X-100/PBS
for 10 min, and blocked with 5% goat serum. Samples were incubated
with primary antibodies overnight at 4C and with secondary antibodies
and/or phalloidin for 2 hr. After washing, coverslips were mounted with
VECTASHIELD (Vector Laboratories). All antibodies used and their dilutions
are listed in Supplemental Experimental Procedures.Chromatin Immunoprecipitation
Cells at 80% confluence were crosslinked with 4% PFA, lysed, and sonicated.
Nuclear lysates were incubated with Protein G Dynabeads (Invitrogen) precon-
jugated with antiestrogen receptor antibody overnight. DNA was reverse
crosslinked and purified by phenol-chloroform and ethanol precipitation.Subcutaneous Tumor Implantation and Metastasis Assay
All animal care and experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of California, San Diego.
Cells (1.5 million) resuspended in 50% Matrigel were injected into the left
and right flanks of Nude mice and allowed to grow to about 2 cm in diameter
before mice were sacrificed. Primary tumor size was measured every 5 days.
Lungs were harvested and imaged for GFP positive tumor cells. Tissues were
embedded in paraffin, sectioned, stained with hematoxylin and eosin, and
imaged to identify GFP positive tumor cells.Three-Dimensional Cell Culture
Equal volumes of neutralized collagen I and Matrigel were mixed on ice and
20 ml added to the bottom of each well of an eight chamber coverglass slide.
Cells of interest were mixed with the Matrigel:collagen mix to give a final
concentration of 200,000 cells per ml and 100 cells ml of the cell:matrix mixture
added to each well. Media was changed every other day until establishment of
spherical colonies. TGFb1 was added at 5 ng/ml every other day for up to
2 weeks. Cells were fixed with 4% PFA and processed as described above
for immunofluorescence.
Cancer Cell
Twist1-Induced Invadopodia Promote MetastasisImmunohistochemistry
Paraffin sections of human or mouse samples were rehydrated through xylene
and graded alcohols. Antigen retrieval was accomplished using a pressure
cooker in 10 mM sodium citrate 0.05% Tween. Samples were incubated
with 3% H2O2 for 30 min followed by 5 hr blocking in 20% goat serum in
PBS. Endogenous biotin and avidin were blocked using a Vector Avidin/Biotin
blocking kit. Primary antibodies were incubated overnight at 4C in 20% goat
serum. Biotinylated secondary antibody and Vectorstain ABC kit were used as
indicated by manufacturer. Samples were developed with diaminobenzidine
(DAB) and samples counterstained with hematoxylin and mounted with
Permount.SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, one table, and Supplemental
Experimental Procedures and can be found online at doi:10.1016/j.ccr.2011.
01.036.
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